US equities |
MU $953.19 ▲+0.00% SNDK $1,482.33 ▲+0.00% ASML $1,717.76 ▲+0.00% SKHY $157.06 ▲+0.00% INTC $102.81 ▲+0.00% NVDA $228.52 ▲+0.00% SPCX $156.54 ▲+0.00% AMD $605.53 ▲+0.00%
FinancialContent

Articles published by Eloxx Pharmaceuticals

News headline image
Eloxx Pharmaceuticals Announces Key Corporate Accomplishments
From Eloxx Pharmaceuticals
Via GlobeNewswire
Tickers DE ELOX
News headline image
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates
From Eloxx Pharmaceuticals
Via GlobeNewswire
Tickers DE ELOX
News headline image
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
From Eloxx Pharmaceuticals
Via GlobeNewswire
Tickers ELOX
News headline image
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
From Eloxx Pharmaceuticals
Via GlobeNewswire
Tickers DE ELOX
News headline image
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
From Eloxx Pharmaceuticals
Via GlobeNewswire
Tickers ELOX
News headline image
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
From Eloxx Pharmaceuticals
Via GlobeNewswire
Tickers ELOX
News headline image
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Eloxx Pharmaceuticals
Via GlobeNewswire
Tickers ELOX
News headline image
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
From Eloxx Pharmaceuticals
Via GlobeNewswire
Tickers ELOX
News headline image
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
From Eloxx Pharmaceuticals
Via GlobeNewswire
Tickers ELOX
News headline image
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update
From Eloxx Pharmaceuticals
Via GlobeNewswire
Tickers ELOX
News headline image
Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
From Eloxx Pharmaceuticals
Via GlobeNewswire
Tickers ELOX
News headline image
Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement
From Eloxx Pharmaceuticals
Via GlobeNewswire
Tickers ELOX
News headline image
Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit
From Eloxx Pharmaceuticals
Via GlobeNewswire
Tickers ELOX
News headline image
Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02
From Eloxx Pharmaceuticals
Via GlobeNewswire
Tickers ELOX
News headline image
Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome
From Eloxx Pharmaceuticals
Via GlobeNewswire
Tickers ELOX
News headline image
Eloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA Congress
From Eloxx Pharmaceuticals
Via GlobeNewswire
Tickers ELOX
News headline image
Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement
From Eloxx Pharmaceuticals
Via GlobeNewswire
Tickers ELOX
News headline image
Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study
From Eloxx Pharmaceuticals
Via GlobeNewswire
Tickers ELOX
News headline image
Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update
From Eloxx Pharmaceuticals
Via GlobeNewswire
Tickers ELOX
News headline image
Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013
From Eloxx Pharmaceuticals
Via GlobeNewswire
Tickers ELOX
News headline image
Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update
From Eloxx Pharmaceuticals
Via GlobeNewswire
Tickers ELOX
News headline image
Eloxx Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application for ZKN-013
From Eloxx Pharmaceuticals
Via GlobeNewswire
Tickers ELOX
News headline image
Eloxx Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
From Eloxx Pharmaceuticals
Via GlobeNewswire
Tickers ELOX
News headline image
Eloxx Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome with First Patient Dosed
From Eloxx Pharmaceuticals
Via GlobeNewswire
Tickers ELOX
News headline image
Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome
From Eloxx Pharmaceuticals
Via GlobeNewswire
Tickers ELOX
News headline image
Eloxx Pharmaceuticals Announces Reverse Stock Split Effective
From Eloxx Pharmaceuticals
Via GlobeNewswire
Tickers ELOX
News headline image
Eloxx Pharmaceuticals Reports Third Quarter 2022 Financial and Operating Results and Provides Business Update
From Eloxx Pharmaceuticals
Via GlobeNewswire
Tickers ELOX
News headline image
Eloxx Pharmaceuticals Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome
From Eloxx Pharmaceuticals
Via GlobeNewswire
Tickers ELOX